LOGIN  |  REGISTER
Amneal Pharmaceuticals
Recursion

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

August 26, 2025 | Last Trade: US$12.07 0.05 0.42

CAMBRIDGE, Mass. / Aug 26, 2025 / Business Wire / Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in the following upcoming investor conferences, which are being conducted in-person in Boston and New York City.

  • Citi's 2025 Biopharma Back to School Conference: Fireside chat on Tuesday, September 2, 2025, at 1:00pm ET
  • Cantor Global Healthcare Conference 2025: Fireside chat on Wednesday, September 3, 2025, at 8:00am ET
  • Morgan Stanley 23rd Annual Global Healthcare Conference: Fireside chat on Monday, September 8, 2025, at 4:50pm ET
  • Baird 2025 Global Healthcare Conference: Fireside chat on Tuesday, September 9, 2025, at 3:10pm ET
  • H.C. Wainwright 27th Annual Global Investment Conference: Corporate presentation on Wednesday, September 10, 2025, at 10:00am ET

A live webcast of each conference event can be accessed under “Events and Presentations” in the Investor section of the Company’s website, https://investors.amylyx.com/events-presentations, and will be available for replay for 90 days following the events.

About Amylyx Pharmaceuticals

At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve. We are currently focused on three investigational therapies across several neurodegenerative and endocrine diseases in which we believe they can make the greatest impact. For more information, visit amylyx.com and follow us on LinkedIn and X. For investors, please visit investors.amylyx.com.

C4 Therapeutics

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page